| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Corixa Corporation, Seattle, WA 98101; Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037; Corixa Corporation, Hamilton, MT 59840; Infectious Disease Research Institute, Seattle, WA 98104; and ¶ Washington National Primate Research Center, University of Washington, Seattle, WA 98195
Current evidence indicates that the chronic inflammation observed in the intestines of patients with inflammatory bowel disease is due to an aberrant immune response to enteric flora. We have developed a lipid A-mimetic, CRX-526, which has antagonistic activity for TLR4 and can block the interaction of LPS with the immune system. CRX-526 can prevent the expression of proinflammatory genes stimulated by LPS in vitro. This antagonist activity of CRX-526 is directly related to its structure, particularly secondary fatty acyl chain length. In vivo, CRX-526 treatment blocks the ability of LPS to induce TNF-
release. Importantly, treatment with CRX-526 inhibits the development of moderate-to-severe disease in two mouse models of colonic inflammation: the dextran sodium sulfate model and multidrug resistance gene 1a-deficient mice. By blocking the interaction between enteric bacteria and the innate immune system, CRX-526 may be an effective therapeutic molecule for inflammatory bowel disease.
This article has been cited by other articles:
|
|
 |
|
  B. Ey, A. Eyking, G. Gerken, D. K. Podolsky, and E. Cario TLR2 Mediates Gap Junctional Intercellular Communication through Connexin-43 in Intestinal Epithelial Barrier Injury J. Biol. Chem., August 14, 2009; 284(33): 22332 - 22343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zanotti, M. Casiraghi, J. B. Abano, J. R. Tatreau, M. Sevala, H. Berlin, S. Smyth, W. K. Funkhouser, K. Burridge, S. H. Randell, et al. Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L52 - L63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ungaro, M. Fukata, D. Hsu, Y. Hernandez, K. Breglio, A. Chen, R. Xu, J. Sotolongo, C. Espana, J. Zaias, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1167 - G1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Mencin, J Kluwe, and R F Schwabe Toll-like receptors as targets in chronic liver diseases Gut, May 1, 2009; 58(5): 704 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Eckmann, T. Nebelsiek, A. A. Fingerle, S. M. Dann, J. Mages, R. Lang, S. Robine, M. F. Kagnoff, R. M. Schmid, M. Karin, et al. Opposing functions of IKK{beta} during acute and chronic intestinal inflammation PNAS, September 30, 2008; 105(39): 15058 - 15063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Spiller, G. Elson, R. Ferstl, S. Dreher, T. Mueller, M. Freudenberg, B. Daubeuf, H. Wagner, and C. J. Kirschning TLR4-induced IFN-{gamma} production increases TLR2 sensitivity and drives Gram-negative sepsis in mice J. Exp. Med., August 4, 2008; 205(8): 1747 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Abrahams Antagonizing Toll-like Receptors to Prevent Preterm Labor Reproductive Sciences, February 1, 2008; 15(2): 108 - 109. [PDF]
|
|
|
|
|
|
C Scarpignato NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut, February 1, 2008; 57(2): 145 - 148. [Full Text] [PDF]
|
|
|
|
|
|
K. M. Adams Waldorf, D. Persing, M. J. Novy, D. W. Sadowsky, and M. G. Gravett Pretreatment With Toll-like Receptor 4 Antagonist Inhibits Lipopolysaccharide-Induced Preterm Uterine Contractility, Cytokines, and Prostaglandins in Rhesus Monkeys Reproductive Sciences, February 1, 2008; 15(2): 121 - 127. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Daubeuf, J. Mathison, S. Spiller, S. Hugues, S. Herren, W. Ferlin, M. Kosco-Vilbois, H. Wagner, C. J. Kirschning, R. Ulevitch, et al. TLR4/MD-2 Monoclonal Antibody Therapy Affords Protection in Experimental Models of Septic Shock J. Immunol., November 1, 2007; 179(9): 6107 - 6114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, R. W. Redline, and Y. W. Han Fusobacterium nucleatum Induces Fetal Death in Mice via Stimulation of TLR4-Mediated Placental Inflammatory Response J. Immunol., August 15, 2007; 179(4): 2501 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M M Heimesaat, A Fischer, H-K Jahn, J Niebergall, M Freudenberg, M Blaut, O Liesenfeld, R R Schumann, U B Gobel, and S Bereswill Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli Gut, July 1, 2007; 56(7): 941 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G De Vry, S. Prasad, L. Komuves, C. Lorenzana, C. Parham, T. Le, S. Adda, J. Hoffman, N. Kahoud, R. Garlapati, et al. Non-viral delivery of nuclear factor-{kappa}B decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis Gut, April 1, 2007; 56(4): 524 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Alderson, P. McGowan, J. R. Baldridge, and P. Probst TLR4 agonists as immunomodulatory agents Innate Immunity, October 1, 2006; 12(5): 313 - 319. [Abstract] [PDF]
|
|
|
|
|
|
T. Jilling, D. Simon, J. Lu, F. J. Meng, D. Li, R. Schy, R. B. Thomson, A. Soliman, M. Arditi, and M. S. Caplan The Roles of Bacteria and TLR4 in Rat and Murine Models of Necrotizing Enterocolitis. J. Immunol., September 1, 2006; 177(5): 3273 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ii, N. Matsunaga, K. Hazeki, K. Nakamura, K. Takashima, T. Seya, O. Hazeki, T. Kitazaki, and Y. Iizawa A Novel Cyclohexene Derivative, Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), Selectively Inhibits Toll-Like Receptor 4-Mediated Cytokine Production through Suppression of Intracellular Signaling Mol. Pharmacol., April 1, 2006; 69(4): 1288 - 1295. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
